United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9 million versus the consensus estimate of $689.93 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.